Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.63 CHF 8.69% Market Closed
Market Cap: 186.9m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Molecular Partners AG
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Accounts Receivables
CHf3.4m
CAGR 3-Years
-25%
CAGR 5-Years
9%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Accounts Receivables
$25.2m
CAGR 3-Years
N/A
CAGR 5-Years
163%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Accounts Receivables
CHf25.4m
CAGR 3-Years
533%
CAGR 5-Years
95%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Accounts Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Accounts Receivables
CHf28.1m
CAGR 3-Years
62%
CAGR 5-Years
44%
CAGR 10-Years
18%
Kuros Biosciences AG
SIX:KURN
Accounts Receivables
CHf9.2m
CAGR 3-Years
73%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
186.9m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
2.91 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Accounts Receivables?
Accounts Receivables
3.4m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Accounts Receivables amounts to 3.4m CHF.

What is Molecular Partners AG's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
9%

Over the last year, the Accounts Receivables growth was 123%. The average annual Accounts Receivables growth rates for Molecular Partners AG have been -25% over the past three years , 9% over the past five years .

Back to Top